

Human alpha-interferon antibody prepn. - by injecting alpha-interferon antigen into animal

Patent Assignee: OTSUKA PHARM CO LTD

Patent Family Patent Number Kind Date Application Number Kind Date Week Type

JP 58225028 A 19831227 JP 82110470 A 19820625 198406 B

JP 92053880 B 19920827 JP 82110470 A 19820625 199239

Priority Applications (Number Kind Date): JP 82110470 A (19820625)

Patent Details Patent Kind Language Page Main IPC Filing Notes

JP 58225028 A 14

JP 92053880 B 92 C07K-015/14 Based on patent JP 58225028

Abstract:

JP 58225028 A

Human alpha-interferon antigen comprising complex of C-terminal peptide of human lymphoblastoid interferon of formula R-Ser-Leu-Ser-Thr-Asn-Gln-Clu -Ser-Leu-Arg-Ser-Lys-Glu-OH (where R is H or H-Tyr-) or its derivative thereof, and carrier, is dosed to mammal, and the formed antigen is taken out.

Antibody is specifically reactive to human alpha-interferons (I), and is used for determin. of (I) by radioimmunoassay or enzyme-immunoassay or for purification of (I) by affinity-chromatography (I) antigen is prepared by reaction of 1 of the peptides (as hapten) and carrier in the presence of hapten-carrier binding agent. Carriers may be natural and synthetic proteins, e.g. animal serum albumin (human serum albumin, bovine serum albumin), animal serum globulin, animal thyroglobulin, animal hemoglobulin, lysine-glutamic acid copolymer, polylysine, polyglutamic acid, etc.. Binding agents are, e.g. aliphatic dialdehydes (glyoxal, malondialdehyde), dimaleimides (N,N'-o-phenylene-dimaleimide), maleimide-carboxyl -N-hydroxysuccinimide-esters, carbodiimides, etc..

Derwent World Patents Index

© 2004 Derwent Information Ltd. All rights reserved.

Dialog® File Number 351 Accession Number 3888691